Amylin Pharmaceuticals — Q1 2009 Earnings Presentation
14 slides from Amylin Pharmaceuticals's earnings presentation, Apr 16, 2009
Slide 1: Amylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes
Amylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes Daniel M. Bradbury President & Chief Executive Officer Mark Foletta Senior VP Finance & Chief Financial Officer Vince Mihalik Senior VP Sales & Marketing & Chief Commercial Officer Orville Kolterman Senior VP Research an
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements about Amylin. Our actual future results could differ materially from those discussed due to a number of factors, including risks that: BYETTA and/or SYMLIN may be affected by competition, safety and other issues; clinical tr
Slide 3: Five Point Plan To Create Value in 2009
Five Point Plan To Create Value in 2009 Gain monotherapy approval Finalize label updates Grow prescriptions 1) BYETTA 2) EXENATIDE ONCE WEEKLY Submit NDA Position for launch Execute DURATION clinical superiority strategy Reduce expenses and improve operating results Positive operating cash flow by t
Slide 4: 1) BYETTA
Five Point Plan To Create Value in 2009 1) BYETTA 4 First and only daily FDA-approved GLP-1 receptor agonist Dual benefits: glucose control and potential weight loss Low risk of hypoglycemia Year 4 on Market: >1 million patients treated Included in American Diabetes Association treatment guidelines
Slide 5: BYETTA
Five Point Plan To Create Value in 2009 5 BYETTA Continued impact of FDA posting on pancreatitis General economic factors Published studies in first quarter: Epidemiologic study published in Current Medical Research and Opinion: Risk of pancreatitis among initiators of BYETTA or JanuviaTM (sitaglipt
Slide 6: Components of FDA submission
Five Point Plan To Create Value in 2009 6 Components of FDA submission DURATION-1: pivotal safety and efficacy DURATION-1 extension: demonstrated comparability of intermediate and commercial material Meta analysis utilized exenatide database: no increased CV risk (0.704 with 95% confidence, 0.378-1.
Slide 7: 2) Exenatide Once Weekly: DURATION-2 Results
Five Point Plan To Create Value in 2009 7 2) EXENATIDE ONCE WEEKLY DURATION-2 Results 26-week clinical study of exenatide once weekly vs. max. doses of JanuviaTM or Actos® (pioglitazone) 491 patients with type 2 diabetes taking stable doses of metformin Evaluable patients randomized to exenatide onc
Slide 8: The Inconvenient Truth: Not All GLP-1 Agonists are Created Equal
8 The Inconvenient Truth: Not All GLP-1 Agonists are Created Equal METABOLISM EXPERIENCE Exenatide is a natural molecule with no chemical modification and functions as a GLP-1 receptor agonist Therapeutic effects achieved at pM levels Exenatide metabolism is known, has no metabolic byproduct – clear
Slide 9: 3) SYMLIN 4) OBESITY
Five Point Plan To Create Value in 2009 9 3) SYMLIN 4) OBESITY 100% owned by Amylin SymlinPen - represents nearly two-thirds of all new prescriptions Sharpened physician targeting Pramlintide/metreleptin phase 2B study results in Q3 Phase 2 davalintide study results in Q4 Finalize funding and develo
Slide 10: Amylin Pharmaceuticals Q1 2009 Operating Results
Amylin Pharmaceuticals Q1 2009 +34% $ (71.1M) $ (47.0M) Net loss +35% $ (0.52) $ (0.34) Net loss per share +55% $ (44.0M) $ (19.9M) Non-GAAP operating loss -22% $ 77.2M $ 60.0M R&D expenses -11% $ 98.2M $ 87.6M SG&A expenses +2% 88% 90% Gross margin % +7% $ 20.2M $ 21.6M* SYMLIN -1% $158.5M $157.7M*
Slide 11: 5) Operating Results: First Quarter 2009
Five Point Plan To Create Value in 2009 11 5) OPERATING RESULTS First Quarter 2009 Progress toward goal of positive operating cash flow by end of 2010 Non-GAAP operating loss $19.9 million compared to $44 million for the same period in 2008 $24.1 Million, or 55%, improvement Cash position remains st
Slide 12: Strengthened Amylin/Lilly Exenatide Operations Through ExenatideOne
Strengthened Amylin/Lilly Exenatide Operations Through “ExenatideOne” 12 Demonstrates both Lilly and Amylin’s long-term commitment to the exenatide franchise Integrated, co-located team to execute plans and address competitive dynamics in the marketplace Improves operational effectiveness Increases
Slide 13: Strong Presence at American Diabetes Association 2009
Strong Presence at American Diabetes Association 2009 More than 20 abstracts accepted Studies reflect the breadth and depth of scientific and clinical programs Provided educational grants to support two medical education symposia Commercial exhibit for Amylin, BYETTA and SYMLIN Annual investor recep
Slide 14: Amylin 2009 Annual Meeting
Amylin 2009 Annual Meeting Annual meeting of shareholders scheduled Wednesday, May 27, 2009 New Board nominees: Paul N. Clark: Former Chairman, CEO & President, ICOS Corporation Paulo F. Costa: Former President & CEO, Norvartis U.S. Corporation 14
Amylin Pharmaceuticals — Q1 2009 Earnings Presentation on 6ix